Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: 613 who wrote (1884)	1/24/2002 2:40:40 PM
From: Cacaito	Read Replies (1) \| Respond to of 2515

"" ''I threw him out,'' said Dr. Leonard A. Herzenberg, a professor of genetics at Stanford; Dr. Waksal worked in his laboratory for a few months in the mid-1970's. Dr. Herzenberg said that for an experiment, Dr. Waksal had supplied him and another researcher with material that turned out not to be what Dr. Waksal had claimed it was. ''I told him, 'You've ruined weeks or months of another postdoc's efforts,' '' Dr. Herzenberg recalled. "" Is this the way a PhD in immunology works? The root of the problem is far back. Who could have any faith in any work done in Erbitux. BMY will do everything to "protect its shareholders", this the best BMY could come with besides "no comments, our good lawyers are working on it".